Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 10 studies | 24% ± 8% | |
type I pneumocyte | 8 studies | 30% ± 9% | |
endothelial cell | 7 studies | 28% ± 10% | |
type II pneumocyte | 6 studies | 27% ± 15% | |
oligodendrocyte | 6 studies | 24% ± 6% | |
abnormal cell | 5 studies | 25% ± 5% | |
ciliated cell | 5 studies | 26% ± 3% | |
classical monocyte | 4 studies | 27% ± 8% | |
epithelial cell | 4 studies | 42% ± 16% | |
platelet | 4 studies | 23% ± 4% | |
pancreatic A cell | 3 studies | 34% ± 13% | |
conventional dendritic cell | 3 studies | 27% ± 10% | |
hematopoietic precursor cell | 3 studies | 28% ± 8% | |
epithelial cell of proximal tubule | 3 studies | 21% ± 5% | |
connective tissue cell | 3 studies | 26% ± 2% | |
pericyte | 3 studies | 19% ± 1% | |
myeloid cell | 3 studies | 24% ± 6% | |
endothelial cell of vascular tree | 3 studies | 17% ± 0% | |
endothelial cell of lymphatic vessel | 3 studies | 24% ± 6% | |
natural killer cell | 3 studies | 18% ± 1% | |
megakaryocyte | 3 studies | 36% ± 10% | |
basal cell | 3 studies | 29% ± 7% | |
hematopoietic stem cell | 3 studies | 27% ± 6% | |
plasmacytoid dendritic cell | 3 studies | 20% ± 3% | |
erythroblast | 3 studies | 38% ± 17% | |
hepatocyte | 3 studies | 43% ± 27% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 4353.47 | 359 / 359 | 99% | 65.36 | 284 / 286 |
lung | 100% | 6199.08 | 578 / 578 | 99% | 71.34 | 1143 / 1155 |
intestine | 100% | 3815.99 | 966 / 966 | 98% | 58.72 | 517 / 527 |
breast | 100% | 4640.06 | 459 / 459 | 98% | 144.45 | 1093 / 1118 |
skin | 99% | 3412.29 | 1796 / 1809 | 98% | 79.09 | 464 / 472 |
pancreas | 100% | 3238.07 | 327 / 328 | 97% | 53.71 | 172 / 178 |
esophagus | 99% | 3200.43 | 1431 / 1445 | 97% | 56.99 | 178 / 183 |
ovary | 100% | 4594.88 | 180 / 180 | 96% | 52.90 | 412 / 430 |
liver | 100% | 9816.23 | 226 / 226 | 95% | 174.60 | 385 / 406 |
kidney | 100% | 5858.16 | 89 / 89 | 94% | 93.03 | 844 / 901 |
prostate | 100% | 3100.04 | 245 / 245 | 93% | 61.64 | 467 / 502 |
brain | 98% | 2673.05 | 2594 / 2642 | 95% | 42.09 | 668 / 705 |
bladder | 100% | 4024.67 | 21 / 21 | 92% | 51.67 | 462 / 504 |
thymus | 100% | 4936.68 | 653 / 653 | 91% | 64.34 | 552 / 605 |
uterus | 100% | 4224.60 | 170 / 170 | 85% | 38.95 | 390 / 459 |
adrenal gland | 100% | 13308.35 | 258 / 258 | 85% | 58.11 | 195 / 230 |
adipose | 100% | 4337.12 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4807.65 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 2679.96 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.68 | 1 / 1 |
peripheral blood | 96% | 2865.86 | 896 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 44.04 | 77 / 80 |
heart | 95% | 2023.49 | 816 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 31.16 | 40 / 45 |
muscle | 80% | 929.02 | 641 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 59% | 22.65 | 17 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0035902 | Biological process | response to immobilization stress |
GO_1900148 | Biological process | negative regulation of Schwann cell migration |
GO_0048681 | Biological process | negative regulation of axon regeneration |
GO_0019216 | Biological process | regulation of lipid metabolic process |
GO_0046513 | Biological process | ceramide biosynthetic process |
GO_1905045 | Biological process | negative regulation of Schwann cell proliferation involved in axon regeneration |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0003677 | Molecular function | DNA binding |
GO_0050291 | Molecular function | sphingosine N-acyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CERS2 |
Protein name | Ceramide synthase 2 Ceramide synthase 2 (CerS2) (LAG1 longevity assurance homolog 2) (SP260) (Sphingosine N-acyltransferase CERS2) (EC 2.3.1.24) (Tumor metastasis-suppressor gene 1 protein) (Very-long-chain ceramide synthase CERS2) (EC 2.3.1.297) |
Synonyms | LASS2 TMSG1 |
Description | FUNCTION: Ceramide synthase that catalyzes the transfer of the acyl chain from acyl-CoA to a sphingoid base, with high selectivity toward very-long-chain fatty acyl-CoA (chain length C22-C27) . N-acylates sphinganine and sphingosine bases to form dihydroceramides and ceramides in de novo synthesis and salvage pathways, respectively (By similarity) . Plays a non-redundant role in the synthesis of ceramides with very-long-chain fatty acids in kidney, liver and brain. Regulates the abundance of myelin-specific sphingolipids galactosylceramide and sulfatide that affects myelin sheath architecture and motor neuron functions (By similarity). . |
Accessions | ENST00000560793.6 H0YLQ6 Q5SZE4 Q5SZE1 ENST00000558062.5 ENST00000368954.10 Q96G23 ENST00000368949.8 ENST00000457392.1 H0YKH6 ENST00000361419.9 Q5SZE2 ENST00000561294.5 H0YNU7 ENST00000271688.10 ENST00000421609.5 Q5SZE3 |